Clinical Scorecard: Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial
At a Glance
Category
Detail
Condition
Moderate to severe plaque psoriasis, a chronic inflammatory skin disease impacting physical, psychological, and social functioning
Key Mechanisms
Bimekizumab is a monoclonal antibody that selectively inhibits IL-17F and IL-17A cytokines involved in psoriasis pathogenesis
Target Population
Patients with moderate to severe plaque psoriasis
Care Setting
Multicenter clinical trial setting including double-blinded and open-label extension phases
Key Highlights
Bimekizumab demonstrated rapid, superior, and durable efficacy compared to secukinumab in treating moderate to severe plaque psoriasis over 3 years
Patient-reported outcomes (PROs) including itching, skin pain, scaling, and Dermatology Life Quality Index (DLQI) showed sustained improvements with bimekizumab
Concurrent achievement of clinical clearance (PASI 0 or ≤2) and quality of life improvements (DLQI 0/1) was reported, indicating meaningful patient benefit
Guideline-Based Recommendations
Diagnosis
Assess psoriasis severity using clinical measures such as Psoriasis Area and Severity Index (PASI) and body surface area (BSA) involvement
Incorporate patient-reported outcome tools like the Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Impacts Measure (P-SIM) to evaluate symptom burden and quality of life
Management
Consider bimekizumab for patients with moderate to severe plaque psoriasis due to its dual IL-17A and IL-17F inhibition and demonstrated long-term efficacy
Use shared decision-making incorporating patient preferences on treatment efficacy, safety, cost, and durability
Transition patients from other IL-17A inhibitors (e.g., secukinumab) to bimekizumab as appropriate
Monitoring & Follow-up
Regularly monitor clinical response using PASI and BSA scores
Evaluate patient-reported symptoms and quality of life using P-SIM and DLQI at baseline and during treatment
Adjust treatment intervals based on clinical response and tolerability (e.g., bimekizumab every 4 or 8 weeks)
Risks
Monitor for adverse events associated with immunomodulatory therapy as per clinical trial safety profiles
Consider patient safety and tolerability when switching therapies or adjusting dosing intervals
Patient & Prescribing Data
Adults with moderate to severe plaque psoriasis enrolled in the BE RADIANT phase 3b trial
Bimekizumab 320 mg administered every 4 or 8 weeks showed sustained symptom relief and quality of life improvements over 3 years, including in patients switching from secukinumab
Clinical Best Practices
Incorporate both clinical severity measures and patient-reported outcomes to guide treatment decisions and assess efficacy
Engage patients in shared decision-making to address treatment preferences and improve adherence
Use validated PRO instruments such as P-SIM and DLQI to capture symptom severity and life impact
Consider long-term treatment plans with bimekizumab to maintain disease control and quality of life
Monitor and document concurrent achievement of clinical clearance and quality of life improvements to evaluate comprehensive treatment success
by Matthias Augustin, Steven R. Feldman, Richard B. Warren, April Armstrong, Ronald Vender, Anna López-Ferrer, William H. Dawe, Jérémy Lambert, Balint Szilagyi, Bengt Hoepken, Rhys Warham, Alice B. Gottlieb
